Drug withdrawals from the Canadian market for safety reasons, 1963-2004

Lexchin, Joel
March 2005
CMAJ: Canadian Medical Association Journal;3/15/2005, Vol. 172 Issue 6, p765
Academic Journal
Examines drug withdrawals from the Canadian market for safety reasons from 1963 to 2004. Significance of longer approval time for drugs; Problems associated with drug withdrawals from the market; Lack of basic information that could be obtained from Health Canada with regard to drugs withdrawn from the market for safety reasons; Examples of drugs withdrawn from the Canadian market.


Related Articles

  • New law requires OTC adverse event reporting. Levy, Sandra // Drug Topics;2/5/2007, Vol. 151 Issue 3, p57 

    The article reports on the new legislation signed into law by U.S. President George W. Bush called the Dietary Supplement and Nonprescription Drug Consumer Protection Act. The law, which is also known as the Adverse Event Reports (AER) bill, requires drug developers to report serious adverse...

  • Who would want to be an inspector? Marwaha, Gurminder // Pharmaceutical Technology Europe;Jun2007, Vol. 19 Issue 6, p8 

    The author reflects on the source of active pharmaceutical ingredients (API) being imported into the European Union (EU). He cites the hard responsibility of being a pharmaceutical inspector as to ensure the safety of the medicines when the call comes out to increase the number of inspections of...

  • Paracetamol legislation 'being ignored.  // Nurse Prescribing;Aug2006, Vol. 4 Issue 7, p268 

    The article reports on the smallscale study discussing the legislation that restricts the usual number of paracetamol tablets that can be purchased at one time. According to the study, the restrictions were brought in to try to cut down the number of reported cases of paracetamol poisonings. The...

  • Should hydrocodone meds shift to Schedule II? Sipkoff, Martin // Drug Topics;5/3/2004, Vol. 148 Issue 9, p38 

    This article talks about the plan of the U.S. Drug Enforcement Administration (DEA) to reclassify medications containing hydrocodone as Schedule II narcotics, making the pain-relieving drugs commonly dispensed as cough suppressant more difficult to prescribe and complicated to dispense....

  • EMEA finalises review of paroxetine-containing medicines.  // Reactions Weekly;5/15/2004, Issue 1001, p2 

    Discusses the finalized review of paroxetine-containing medicines by the European Agency for the Evaluation of Medicinal Products in April 2004. Move of Great Britain to initiate the review in June 2003; Conclusion on the benefit-risk profile for paroxetine; Recommendations of the agency on the...

  • Ottawa passes drug safety law. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;8/5/2014, Vol. 186 Issue 11, p818 

    The article reports that Ottawa's House of Commons approved the Bill C-17, a drug safety law which amends the Food and Drugs Act. Topics discussed include the law to give authority to the minister of health to order a drug off the market if surveillance data showed a serious risk, authority for...

  • Drug Distribution and Control.  // Best Practices for Hospital & Health-System Pharmacy;2007/2008, p21 

    The article presents several policies on drug distribution and control in the U.S. The policy on the Redistribution of Unused Medications from the Council on Legal and Public Affairs aims to advocate that any program for return and reuse of medications comply with all federal and state laws so...

  • FDA poised for broader powers over drugs on sale.  // Nature;9/27/2007, Vol. 449 Issue 7161, p390 

    The article reports on the move of the U.S. Congress to pass a bill that will increase the powers of Food and Drug Administration (FDA) to guard the safety of marketed drugs. It is stated that under the new law, FDA will be able to order companies to make label changes on marketed drugs. It is...

  • President's column: AMIA's policy priorities for 2014. Middleton, Blackford // Journal of the American Medical Informatics Association;May2014, Vol. 21 Issue 3, p574 

    In this article the author reflects on the 2014 policy priorities of the American Medical Informatics Association and discusses the association's goals. A discussion of the association's involvement with the U.S. Food and Drug Administration Safety and Innovation Act, and of the aims and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics